Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

However, a third drug also FDA-approved for weight loss, liraglutide (Saxenda), didn’t work as well as the others, researchers found after reviewing data from dozens of clinical trials.

There are currently three medications (GLP-1s) on the market that the FDA has specifically approved to treat obesity — Wegovy, Zepbound, or Saxenda. Other common weight-loss medications like ...